相关临床试验
199
17 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
9
4.5%
已完成
116
58.3%
Enrolling By Invitation
1
0.5%
尚未招募
7
3.5%
招募中
20
10.1%
暂停
3
1.5%
终止
28
14.1%
Unknown
1
0.5%
撤回
14
7.0%
暂无批准数据
- A Virginia physician woke to find a bat attempting to enter her mouth, prompting immediate emergency evaluation and rabies testing that ultimately returned negative. - Bats are the leading source of human rabies in the U.S., causing at least 7 out of 10 rabies fatalities, with two-thirds of annual rabies shots linked to bat exposure. - Experts advise that any direct physical contact with a bat, especially waking in a room with one, should be treated as a high-risk exposure requiring prompt medical assessment. - Post-exposure prophylaxis should begin as soon as possible after exposure, though rabies is considered a medical urgency rather than an emergency because infection spread takes days.
- The CAVIAR trial demonstrated that alirocumab combined with rosuvastatin safely reduced LDL cholesterol levels by more than 50% in heart transplant patients within one year. - Despite significant cholesterol reduction, the study did not show meaningful differences in coronary plaque progression between treatment groups. - The findings support PCSK9 inhibitor use for cholesterol management in transplant patients, though longer-term studies are needed to assess impact on cardiac allograft vasculopathy prevention. - Both treatment regimens were well-tolerated with no significant adverse events reported in the 114-patient randomized controlled trial.
- Cardurion Pharmaceuticals has completed enrollment in two Phase 2 trials evaluating CRD-750, the first clinical-stage PDE9 inhibitor for chronic heart failure treatment. - The CYCLE trials enrolled approximately 860 patients across both heart failure subtypes, with CYCLE-1-REF testing three doses in 560 HFrEF patients and CYCLE-2-PEF evaluating one dose in 300 HFpEF patients. - CRD-750 targets phosphodiesterase 9 inhibition to enhance natriuretic peptide signaling, addressing a significant unmet medical need in heart failure where 50% of patients die within five years of diagnosis. - The trials use NT-proBNP reduction as the primary endpoint, a validated biomarker previously used in approved heart failure therapies, with results expected to be presented at future medical meetings.
- An international research team has developed and validated the first individualized risk prediction model for early-stage classic Hodgkin's lymphoma, called the Early-stage Hodgkin International Prognostication Index (E-HIPI). - The model was developed using data from over 3,000 patients in four international phase III clinical trials and validated in more than 2,300 patients from real-world registry cohorts. - E-HIPI uses routine clinical measures like patient sex, tumor size, hemoglobin and albumin levels to predict two-year progression-free survival and outperformed existing classification systems. - The research team created interactive online risk calculators to support shared decision-making between clinicians and patients, with findings published in NEJM Evidence.
- A phase III clinical trial demonstrated that dendritic cell therapy (DCVax-L) extended median overall survival to 13.2 months in recurrent glioblastoma patients compared to 7.8 months in controls, representing a 68% increase in survival. - Long-term survival outcomes showed 20.7% of treated patients alive at 24 months after recurrence, compared to only 9.6% in the control group. - The therapy works by training the patient's immune system to recognize and attack glioblastoma tumor cells using autologous dendritic cells loaded with tumor antigens. - Dendritic cell vaccination is generally well-tolerated with mostly mild side effects, offering a safer alternative to traditional chemotherapy for this aggressive brain cancer.
- OKYO Pharma's Phase 2 trial for urcosimod, a potential first-in-class treatment for neuropathic corneal pain, closed early after treating 17 patients instead of the planned 48, with top-line results now expected in Q3 2025. - Goldman Small Cap Research raised its price target for OKYO shares to $8 from $5, citing the early trial closure as potentially shortening the development pathway and accelerating time to market. - The drug targets neuropathic corneal pain, a debilitating condition with no FDA-approved therapies and an estimated market opportunity exceeding $6.4 billion. - OKYO's shares have nearly doubled since the start of 2025, driven by clinical progress and the FDA's Fast Track designation for urcosimod.
- CereVasc's eShunt System received its second FDA Breakthrough Device Designation for treating communicating hydrocephalus in pediatric patients aged 12 and older, enabling priority review and enhanced regulatory communication. - Research published in the Journal of NeuroInterventional Surgery demonstrated that endovascular shunt placement was feasible in 67% of pediatric patients studied, with no statistically significant age-based differences in eligibility. - The minimally invasive eShunt System previously achieved primary safety and efficacy endpoints in a US study of 30 elderly patients with Normal Pressure Hydrocephalus, with 97% showing symptom improvement.
• CereVasc has initiated the STRIDE pivotal trial at VCU Health, comparing their novel eShunt System to traditional VP shunts for normal pressure hydrocephalus treatment. • The eShunt System represents the first new treatment option for NPH in over 60 years, offering a minimally invasive endovascular approach to address this condition affecting 800,000 Americans. • The trial aims to demonstrate improved recovery times and reduced complications compared to standard VP shunts, potentially making treatment accessible to more patients with comorbidities.
- OKYO Pharma expects to complete enrollment of 48 patients in its Phase 2a trial of OK-101, the first FDA-cleared investigational drug specifically for neuropathic corneal pain, by Q2 2025. - The company recently reported positive Phase 2b results for OK-101 in dry eye disease, showing significant improvements in conjunctival staining and symptom reduction with a favorable safety profile. - The Phase 2a NCP trial, led by renowned expert Dr. Pedram Hamrah at Tufts Medical Center, is designed as a double-masked, randomized, 12-week placebo-controlled study.
- Research from Tufts Medical Center reveals 15% of health plans have inconsistent coverage requirements between medical and pharmacy benefits for the same specialty drugs, creating patient access challenges. - Vertical integration of pharmacy benefit managers (PBMs) with insurers drives the shift of specialty drugs from medical to pharmacy benefits, leading to complex navigation requirements for patients. - White and brown bagging practices, aimed at maximizing profits through insurer-owned pharmacies, may increase system waste and burden patients with additional drug management responsibilities.
